[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363312-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-363312-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","from-diabetes-to-tumor-growth-unravelling-the-impact-of-glucose-lowering-therapies","From diabetes to tumor growth - unravelling the impact of glucose-lowering therapies","","Diabetes mellitus and cancer represent two expanding global health burdens with shared upstream determinants, while diabetes may also increase malignancy risk through hyperglycaemia/AGE-related stress, insulin resistance with compensatory hyperinsulinaemia, obesity-linked inflammation, and modulation of the tumour microenvironment. This narrative review synthesizes mechanistic plausibility and critically appraises the highest-level clinical evidence on oncologic safety signals for glucose-lowering therapies, emphasizing cancer incidence captured within randomized diabetes trials.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/from-diabetes-to-tumor-growth-unravelling-the-impact-of-glucose-lowering-therapies/363312/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/from-diabetes-to-tumor-growth-unravelling-the-impact-of-glucose-lowering-therapies/363312.png","ImageObject",300,407,{"name":42,"@type":43},"Stanford","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",16,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How do diabetes and cancer share upstream determinants in this review?","Question",{"text":63,"@type":64},"The review highlights common upstream determinants that contribute to both diabetes and cancer, while diabetes may further promote malignancy risk through metabolic and microenvironmental pathways.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which diabetes drug classes are assessed for oncologic safety in the results?",{"text":68,"@type":64},"The review covers metformin, thiazolidinediones, GLP-1 receptor agonists (and dual GLP-1/GIP agonists), SGLT2 inhibitors, and insulin, summarizing their effects on cancer incidence and site-specific risks.",{"name":70,"@type":61,"acceptedAnswer":71},"What limitations affect the interpretation of the evidence?",{"text":72,"@type":64},"The conclusion notes constraints including non-prespecified endpoints, limited oncologic adjudication, short follow-up relative to tumour latency, low site-specific event counts, and potential competing-risk effects.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},363312,1790482065,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":128,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336477552062,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Endocrine (2026) 91:176  \n[https://doi.org/10.1007/s12020-026-04644-1](https://doi.org/10.1007/s12020-026-04644-1)  \nREVIEW  \nFrom diabetes to tumor growth: unravelling the impact of glucoselowering therapies  \nR. Modica1 · A. Liccardi1 · V. Zamponi2 · A. Gagliardi3 · A. Nistor3 · G. Veroi4 · A. Arecco5 · A. Faggiano2 · A. Colao1  \nReceived: 14 January 2026 / Accepted: 8 April 2026 © The Author(s) 2026  \nAbstract  \nPurpose Diabetes mellitus and cancer are two expanding global health burdens that share upstream determinants, yet diabetes may also contribute to malignancy risk through hyperglycaemia/AGE-related stress, insulin resistance with compensatory hyperinsulinaemia, obesity-related inflammation, and tumour microenvironment modulation. This narrative review synthesizes mechanistic plausibility and critically appraises the highest-level clinical evidence on the oncologic safety signals of glucose-lowering therapies, with a focus on cancer incidence captured within randomized diabetes trials.  \nMethods argeted searches of PubMed/MEDLINE and Embase were complemented by manual reference screening. Mechanistic and translational data were summarized separately from clinical evidence. For each drug class, we prioritized pivotal randomized controlled trials and cardiovascular outcome trials (phase 3–4, large, practice-defining), extracting malignancy reporting collected as adverse events/serious adverse events or events of special interest. When randomized evidence was limited, high-quality meta-analyses and selected real-world studies were used for context, clearly distinguished from prespecified randomized evidence.  \nResults Metformin shows a predominantly neutral effect on cancer incidence, with possible indirect protective signals but no trials specifically designed to assess chemoprevention. Thiazolidinediones demonstrate an overall neutral malignancy profile, with early concerns regarding bladder cancer not confirmed in adjudicated analyses. GLP-1 receptor agonists and dual GLP-1/GIP agonists consistently show no increase in overall or site-specific cancer risk, with emerging signals of reduced obesity-related malignancies. SGLT2 inhibitors display class-wide oncologic neutrality, with heterogeneous and inconclusive drug-specific patterns in meta-analyses. Randomized evidence confirms that insulin, including long-acting analogues, does not increase cancer risk.  \nConclusion Current randomized evidence supports a predominantly neutral effect of antidiabetic therapies on cancer incidence, with some agents showing promising signals of protection. This interpretation is constrained by non-prespecified endpoints, limited oncologic adjudication, short follow-up relative to tumour latency, low site-specific event counts, and potential competing-risk effects. Dedicated long-term trials and registry-linkage strategies with cancer-focused endpoints are needed to clarify whether any therapies confer true protection or warrant targeted monitoring.  \nKeywords cancer · risk factor · antidiabetics drugs · tumors · diabetes  \n􀀍 R. Modica [roberta.modica@unina.it](roberta.modica@unina.it)  \n1 Endocrinology, Diabetology and Andrology Unit, Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy  \n2 Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy  \n3 Department of Experimental Medicine, Section of Medical Physiopathology, Nutrition Science and Endocrinology, Sapienza University, Rome, Italy  \n4 Department of Endocrinology, San Camillo-Forlanini Hospital, Rome 00152, Italy  \n5 Endocrinology Unit, Department of Internal Medicine and Medical Specialties, School of Medical and Pharmaceutical Sciences, University of Genova, Genova 16132, Italy  \n1 3  \nIntroduction  \nOver the past few decades, the global public health landscape has undergone profound changes driven by the escalating prevalence of chronic noncommunicable diseases (NCDs) . Among these, diabetes mellitus and","cbCaikIjsx0mLeTS","https://ap.wps.com/l/cbCaikIjsx0mLeTS","pdf",1443159,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Materials and methods","[{\"question\":\"How do diabetes and cancer share upstream determinants in this review?\",\"answer\":\"The review highlights common upstream determinants that contribute to both diabetes and cancer, while diabetes may further promote malignancy risk through metabolic and microenvironmental pathways.\"},{\"question\":\"Which diabetes drug classes are assessed for oncologic safety in the results?\",\"answer\":\"The review covers metformin, thiazolidinediones, GLP-1 receptor agonists (and dual GLP-1/GIP agonists), SGLT2 inhibitors, and insulin, summarizing their effects on cancer incidence and site-specific risks.\"},{\"question\":\"What limitations affect the interpretation of the evidence?\",\"answer\":\"The conclusion notes constraints including non-prespecified endpoints, limited oncologic adjudication, short follow-up relative to tumour latency, low site-specific event counts, and potential competing-risk effects.\"}]","From diabetes to tumor growth - unravelling the impact of glucose-lowering therapies | PDF",1790150752,48,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e05e17919e2e9b3d0fc017c46f5b3a6e.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/63317b3a7173542f27b942340da6b455.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a59060b4bb5e698f8eb8a82af291320.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/54f9cef8a3d3a131b21919fd6736815b.webp",980,1301]